Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease

Dysregulated protease activity has long been implicated in the pathogenesis of chronic lung diseases and especially in conditions that display mucus obstruction, such as chronic obstructive pulmonary disease, cystic fibrosis, and non-cystic fibrosis bronchiectasis. However, our appreciation of the r...

Full description

Bibliographic Details
Main Authors: Michael C. McKelvey, Ryan Brown, Sinéad Ryan, Marcus A. Mall, Sinéad Weldon, Clifford C. Taggart
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/22/9/5018
id doaj-03931cfe7b8042028b2fda15d87b3de2
record_format Article
spelling doaj-03931cfe7b8042028b2fda15d87b3de22021-05-31T23:31:24ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-05-01225018501810.3390/ijms22095018Proteases, Mucus, and Mucosal Immunity in Chronic Lung DiseaseMichael C. McKelvey0Ryan Brown1Sinéad Ryan2Marcus A. Mall3Sinéad Weldon4Clifford C. Taggart5Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast BT9 7BL, UKAirway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast BT9 7BL, UKAirway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast BT9 7BL, UKDepartment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité—Universitätsmedizin Berlin, 13353 Berlin, GermanyAirway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast BT9 7BL, UKAirway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast BT9 7BL, UKDysregulated protease activity has long been implicated in the pathogenesis of chronic lung diseases and especially in conditions that display mucus obstruction, such as chronic obstructive pulmonary disease, cystic fibrosis, and non-cystic fibrosis bronchiectasis. However, our appreciation of the roles of proteases in various aspects of such diseases continues to grow. Patients with muco-obstructive lung disease experience progressive spirals of inflammation, mucostasis, airway infection and lung function decline. Some therapies exist for the treatment of these symptoms, but they are unable to halt disease progression and patients may benefit from novel adjunct therapies. In this review, we highlight how proteases act as multifunctional enzymes that are vital for normal airway homeostasis but, when their activity becomes immoderate, also directly contribute to airway dysfunction, and impair the processes that could resolve disease. We focus on how proteases regulate the state of mucus at the airway surface, impair mucociliary clearance and ultimately, promote mucostasis. We discuss how, in parallel, proteases are able to promote an inflammatory environment in the airways by mediating proinflammatory signalling, compromising host defence mechanisms and perpetuating their own proteolytic activity causing structural lung damage. Finally, we discuss some possible reasons for the clinical inefficacy of protease inhibitors to date and propose that, especially in a combination therapy approach, proteases represent attractive therapeutic targets for muco-obstructive lung diseases.https://www.mdpi.com/1422-0067/22/9/5018chronic lung diseaseproteasesantiproteasesmucusmuco-obstructive lung diseasemucociliary clearance
collection DOAJ
language English
format Article
sources DOAJ
author Michael C. McKelvey
Ryan Brown
Sinéad Ryan
Marcus A. Mall
Sinéad Weldon
Clifford C. Taggart
spellingShingle Michael C. McKelvey
Ryan Brown
Sinéad Ryan
Marcus A. Mall
Sinéad Weldon
Clifford C. Taggart
Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease
International Journal of Molecular Sciences
chronic lung disease
proteases
antiproteases
mucus
muco-obstructive lung disease
mucociliary clearance
author_facet Michael C. McKelvey
Ryan Brown
Sinéad Ryan
Marcus A. Mall
Sinéad Weldon
Clifford C. Taggart
author_sort Michael C. McKelvey
title Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease
title_short Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease
title_full Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease
title_fullStr Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease
title_full_unstemmed Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease
title_sort proteases, mucus, and mucosal immunity in chronic lung disease
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2021-05-01
description Dysregulated protease activity has long been implicated in the pathogenesis of chronic lung diseases and especially in conditions that display mucus obstruction, such as chronic obstructive pulmonary disease, cystic fibrosis, and non-cystic fibrosis bronchiectasis. However, our appreciation of the roles of proteases in various aspects of such diseases continues to grow. Patients with muco-obstructive lung disease experience progressive spirals of inflammation, mucostasis, airway infection and lung function decline. Some therapies exist for the treatment of these symptoms, but they are unable to halt disease progression and patients may benefit from novel adjunct therapies. In this review, we highlight how proteases act as multifunctional enzymes that are vital for normal airway homeostasis but, when their activity becomes immoderate, also directly contribute to airway dysfunction, and impair the processes that could resolve disease. We focus on how proteases regulate the state of mucus at the airway surface, impair mucociliary clearance and ultimately, promote mucostasis. We discuss how, in parallel, proteases are able to promote an inflammatory environment in the airways by mediating proinflammatory signalling, compromising host defence mechanisms and perpetuating their own proteolytic activity causing structural lung damage. Finally, we discuss some possible reasons for the clinical inefficacy of protease inhibitors to date and propose that, especially in a combination therapy approach, proteases represent attractive therapeutic targets for muco-obstructive lung diseases.
topic chronic lung disease
proteases
antiproteases
mucus
muco-obstructive lung disease
mucociliary clearance
url https://www.mdpi.com/1422-0067/22/9/5018
work_keys_str_mv AT michaelcmckelvey proteasesmucusandmucosalimmunityinchroniclungdisease
AT ryanbrown proteasesmucusandmucosalimmunityinchroniclungdisease
AT sineadryan proteasesmucusandmucosalimmunityinchroniclungdisease
AT marcusamall proteasesmucusandmucosalimmunityinchroniclungdisease
AT sineadweldon proteasesmucusandmucosalimmunityinchroniclungdisease
AT cliffordctaggart proteasesmucusandmucosalimmunityinchroniclungdisease
_version_ 1721417242162233344